Polydopamine-based nanomedicines for efficient antiviral and secondary injury protection therapy

Sci Adv. 2023 Jun 16;9(24):eadf4098. doi: 10.1126/sciadv.adf4098. Epub 2023 Jun 14.

Abstract

Viral infections continue to threaten human health. It remains a major challenge to efficiently inhibit viral infection while avoiding secondary injury. Here, we designed a multifunctional nanoplatform (termed as ODCM), prepared by oseltamivir phosphate (OP)-loaded polydopamine (PDA) nanoparticles camouflaged by the macrophage cell membrane (CM). OP can be efficiently loaded onto the PDA nanoparticles through the π-π stacking and hydrogen bonding interactions with a high drug-loading rate of 37.6%. In particular, the biomimetic nanoparticles can accumulate actively in the damaged lung model of viral infection. At the infection site, PDA nanoparticles can consume excess reactive oxygen species and be simultaneously oxidized and degraded to achieve controlled release of OP. This system exhibits enhanced delivery efficiency, inflammatory storm suppression, and viral replication inhibition. Therefore, the system exerts outstanding therapeutic effects while improving pulmonary edema and protecting lung injury in a mouse model of influenza A virus infection.

MeSH terms

  • Animals
  • Antiviral Agents* / pharmacology
  • Humans
  • Indoles / pharmacology
  • Mice
  • Nanomedicine*
  • Oseltamivir

Substances

  • Antiviral Agents
  • polydopamine
  • Oseltamivir
  • Indoles